Log in

Bristol-Myers Squibb News Headlines (NYSE:BMY)

$53.03
+0.61 (+1.16 %)
(As of 10/21/2019 03:23 AM ET)
Today's Range
$52.38
Now: $53.03
$53.17
50-Day Range
$47.58
MA: $49.95
$52.82
52-Week Range
$42.48
Now: $53.03
$55.85
Volume10.61 million shs
Average Volume9.98 million shs
Market Capitalization$86.74 billion
P/E Ratio13.32
Dividend Yield3.13%
Beta0.72

Headlines

Bristol-Myers Squibb (NYSE BMY) News Headlines

Source:
DateHeadline
Bristol-Myers Squibb Co (NYSE:BMY) Receives Average Recommendation of "Buy" from AnalystsBristol-Myers Squibb Co (NYSE:BMY) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - October 20 at 1:46 PM
Bristol-Myers extends date for exchange offer of Celgene notesBristol-Myers extends date for exchange offer of Celgene notes
seekingalpha.com - October 18 at 1:16 PM
Insulin Market to See Major Growth by 2025 | Novartis, Novo Nordisk, Boehringer Ingelheim, Bristol-Myers SquibbInsulin Market to See Major Growth by 2025 | Novartis, Novo Nordisk, Boehringer Ingelheim, Bristol-Myers Squibb
www.marketwatch.com - October 17 at 8:15 AM
Bristol-Myers Squibb (NYSE:BMY) Coverage Initiated at Bank of AmericaBristol-Myers Squibb (NYSE:BMY) Coverage Initiated at Bank of America
www.americanbankingnews.com - October 16 at 5:58 PM
3 Reasons Bristol-Myers Could Still Double From Here3 Reasons Bristol-Myers Could Still Double From Here
seekingalpha.com - October 16 at 1:07 PM
Bristol-Myers Squibb (BMY) Stock Moves -0.1%: What You Should KnowBristol-Myers Squibb (BMY) Stock Moves -0.1%: What You Should Know
finance.yahoo.com - October 14 at 10:36 PM
Roche Announces Positive Late-Stage Data on Rituxan in PVRoche Announces Positive Late-Stage Data on Rituxan in PV
finance.yahoo.com - October 14 at 12:35 PM
Bristol-Myers Squibb (NYSE:BMY) Stock Rating Reaffirmed by Bank of AmericaBristol-Myers Squibb (NYSE:BMY) Stock Rating Reaffirmed by Bank of America
www.americanbankingnews.com - October 10 at 11:44 AM
Bristol-Myers Squibb: Could BMY Stock Surge Higher?Bristol-Myers Squibb: Could BMY Stock Surge Higher?
finance.yahoo.com - October 8 at 10:35 PM
Signs That Your Trading Will Ruin Your Retirement - October 08, 2019Signs That Your Trading Will Ruin Your Retirement - October 08, 2019
finance.yahoo.com - October 8 at 5:34 PM
Why Alexion is a Hot Takeover Target in the Biotech SectorWhy Alexion is a Hot Takeover Target in the Biotech Sector
finance.yahoo.com - October 8 at 12:34 PM
Infinity's (INFI) IPI-549 in Focus in a Crowded Cancer SpaceInfinity's (INFI) IPI-549 in Focus in a Crowded Cancer Space
finance.yahoo.com - October 8 at 12:34 PM
Global Lymphopenia Therapeutics Market 2019-2023 | Evolving Opportunities with Bristol-Myers Squibb Co. and CSL Ltd. | TechnavioGlobal Lymphopenia Therapeutics Market 2019-2023 | Evolving Opportunities with Bristol-Myers Squibb Co. and CSL Ltd. | Technavio
www.finanznachrichten.de - October 8 at 2:33 AM
Global Lymphopenia Therapeutics Market 2019-2023 | Evolving Opportunities with Bristol-Myers Squibb Co. and CSL Ltd. |Global Lymphopenia Therapeutics Market 2019-2023 | Evolving Opportunities with Bristol-Myers Squibb Co. and CSL Ltd. |
www.bloomberg.com - October 8 at 2:33 AM
Bristol-Myers sues Dr. Reddys to block generic SprycelBristol-Myers sues Dr. Reddy's to block generic Sprycel
seekingalpha.com - October 7 at 8:18 PM
How Does Bristol-Myers Squibb’s Valuation Compare To Its Peers?How Does Bristol-Myers Squibb’s Valuation Compare To Its Peers?
www.forbes.com - October 7 at 5:34 AM
HIV Drugs Market to See Major Growth by 2025 | Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKlineHIV Drugs Market to See Major Growth by 2025 | Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline
www.marketwatch.com - October 5 at 1:48 PM
3 Drug Stocks Poised for Gains After Cancer Conference3 Drug Stocks Poised for Gains After Cancer Conference
finance.yahoo.com - October 4 at 3:56 PM
$5.83 Billion in Sales Expected for Bristol-Myers Squibb Co (NYSE:BMY) This Quarter$5.83 Billion in Sales Expected for Bristol-Myers Squibb Co (NYSE:BMY) This Quarter
www.americanbankingnews.com - October 4 at 6:29 AM
Bristol-Myers Squibb On Roll With Opdivo ResultsBristol-Myers Squibb On Roll With Opdivo Results
seekingalpha.com - October 3 at 5:12 PM
Japan drug price reforms risk hurting investment -Bristol-Myers CEOJapan drug price reforms risk hurting investment -Bristol-Myers CEO
finance.yahoo.com - October 3 at 6:44 AM
Najarian Brothers See Unusual Options Activity In Bristol-Myers, AMD And MoreNajarian Brothers See Unusual Options Activity In Bristol-Myers, AMD And More
finance.yahoo.com - October 1 at 3:44 PM
Why Bristol-Myers (BMY) is Poised to Beat Earnings Estimates AgainWhy Bristol-Myers (BMY) is Poised to Beat Earnings Estimates Again
finance.yahoo.com - October 1 at 3:44 PM
BRIEF-Bristol-Myers Opdivo Shows Significant Overall Survival Benefit Vs. Chemotherapy In Esophageal Cancer PatientsBRIEF-Bristol-Myers' Opdivo Shows Significant Overall Survival Benefit Vs. Chemotherapy In Esophageal Cancer Patients
www.msn.com - September 30 at 10:29 PM
Bristol-Myers Squibb (BMY) Presents At ESMO Congress 2019 - SlideshowBristol-Myers Squibb (BMY) Presents At ESMO Congress 2019 - Slideshow
seekingalpha.com - September 30 at 5:28 PM
Opdivo (nivolumab) Demonstrates Statistically Significant Overall Survival Benefit Versus Chemotherapy in Patients with Advanced Esophageal CancerOpdivo (nivolumab) Demonstrates Statistically Significant Overall Survival Benefit Versus Chemotherapy in Patients with Advanced Esophageal Cancer
finance.yahoo.com - September 30 at 5:27 PM
Why You Might Be Interested In Bristol-Myers Squibb Company (NYSE:BMY) For Its Upcoming DividendWhy You Might Be Interested In Bristol-Myers Squibb Company (NYSE:BMY) For Its Upcoming Dividend
finance.yahoo.com - September 29 at 2:59 AM
BRIEF-Bristol-Myers Squibb Says 5-Year Results For Opdivo In Combination With Yervoy Showed Durable Long-Term Survival BenefitsBRIEF-Bristol-Myers Squibb Says 5-Year Results For Opdivo In Combination With Yervoy Showed Durable Long-Term Survival Benefits
www.msn.com - September 28 at 9:59 PM
Bristol-Myers Cancer Combo Has Tepid Result Against ChemotherapyBristol-Myers Cancer Combo Has Tepid Result Against Chemotherapy
www.bloomberg.com - September 28 at 4:58 PM
Bristol-Myers immunotherapy combo outperforms chemo in lung cancer survival: studyBristol-Myers immunotherapy combo outperforms chemo in lung cancer survival: study
www.reuters.com - September 28 at 4:58 PM
Bristol-Myers Squibb Announces Final Results from CheckMate -227 Part 1 Demonstrating Superior Overall Survival for Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) vs. Chemotherapy in Advanced Non-Small Cell Lung CancerBristol-Myers Squibb Announces Final Results from CheckMate -227 Part 1 Demonstrating Superior Overall Survival for Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) vs. Chemotherapy in Advanced Non-Small Cell Lung Cancer
www.businesswire.com - September 28 at 11:15 AM
A Comprehensive Study Exploring AIDS Related Cancer Market | Key Players Bristol Myers Squibb, Takeda Pharmaceuticals, Gilead SciencesA Comprehensive Study Exploring AIDS Related Cancer Market | Key Players Bristol Myers Squibb, Takeda Pharmaceuticals, Gilead Sciences
www.marketwatch.com - September 25 at 7:29 AM
Is Bristol-Myers (BMY) a Solid Growth Stock? 3 Reasons to Think " Yes "Is Bristol-Myers (BMY) a Solid Growth Stock? 3 Reasons to Think " Yes "
www.msn.com - September 24 at 9:28 PM
Bristol-Myers Squibb Brings In Big Dividend Next WeekBristol-Myers Squibb Brings In Big Dividend Next Week
www.forbes.com - September 24 at 4:27 PM
Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) Four-Week Dosing Schedule for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease who have...Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) Four-Week Dosing Schedule for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease who have...
finance.yahoo.com - September 24 at 7:44 AM
Carter Worth And Mike Khouws Bristol-Myers Squibb Options TradeCarter Worth And Mike Khouw's Bristol-Myers Squibb Options Trade
www.benzinga.com - September 23 at 4:36 PM
Top Analyst Reports for Bristol-Myers Squibb, Lockheed Martin & AlphabetTop Analyst Reports for Bristol-Myers Squibb, Lockheed Martin & Alphabet
finance.yahoo.com - September 23 at 4:36 PM
Does Bristol-Myers Squibb Companys (NYSE:BMY) CEO Pay Reflect Performance?Does Bristol-Myers Squibb Company's (NYSE:BMY) CEO Pay Reflect Performance?
finance.yahoo.com - September 20 at 11:53 AM
Bristol-Myers Squibb to Hold Investor Webcast to Discuss ESMO HighlightsBristol-Myers Squibb to Hold Investor Webcast to Discuss ESMO Highlights
www.marketwatch.com - September 20 at 11:53 AM
Zacks Value Trader Highlights: Exact Sciences, Edwards Lifesciences, Bristol Myers-Squibb, Occidental Petroleum and Exxon MobilZacks Value Trader Highlights: Exact Sciences, Edwards Lifesciences, Bristol Myers-Squibb, Occidental Petroleum and Exxon Mobil
finance.yahoo.com - September 20 at 11:53 AM
Bristol-Myers Squibb Research at ESMO Demonstrates Breadth of Oncology Development Program and Focus on Improving Overall Survival Across Multiple CancersBristol-Myers Squibb Research at ESMO Demonstrates Breadth of Oncology Development Program and Focus on Improving Overall Survival Across Multiple Cancers
www.businesswire.com - September 19 at 8:28 AM
Healthy Dividends: Finding Refuge In Bristol-Myers SquibbHealthy Dividends: Finding Refuge In Bristol-Myers Squibb
seekingalpha.com - September 18 at 6:27 PM
Bristol-Myers Stock Is Looking Good After Otezla Deal, Analyst SaysBristol-Myers Stock Is Looking Good After Otezla Deal, Analyst Says
www.barrons.com - September 13 at 3:50 PM
Bristol‘Myers Squibb Announces DividendBristol‘Myers Squibb Announces Dividend
www.marketwatch.com - September 12 at 12:50 PM
CEL-SCIs Multikine Trial: Learning From Bristol-Myers IpilimumabCEL-SCI's Multikine Trial: Learning From Bristol-Myers' Ipilimumab
seekingalpha.com - September 12 at 12:50 PM
Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock Right NowWhy Bristol-Myers Squibb (BMY) is a Great Dividend Stock Right Now
www.msn.com - September 11 at 5:37 AM
Global Yervoy Market 2019- Bristol-Myers SquibbGlobal Yervoy Market 2019- Bristol-Myers Squibb
www.marketwatch.com - September 11 at 5:37 AM
Bristol-Myers Opdivo shows sustained survival benefit in NSCLCBristol-Myers' Opdivo shows sustained survival benefit in NSCLC
seekingalpha.com - September 11 at 5:37 AM
Bristol-Myers Squibbs Revenues: How Does Bristol-Myers Squibb Make Money?Bristol-Myers Squibb's Revenues: How Does Bristol-Myers Squibb Make Money?
www.nasdaq.com - September 11 at 5:37 AM
Biohaven Advances NOJECTION(TM) Migraine Platform With Completion Of Enrollment Of Pivotal Phase 2/3 Trial Of Vazegepant, The First Intranasally Administered CGRP Receptor Antagonist In Development For The Acute Treatment Of MigraineBiohaven Advances NOJECTION(TM) Migraine Platform With Completion Of Enrollment Of Pivotal Phase 2/3 Trial Of Vazegepant, The First Intranasally Administered CGRP Receptor Antagonist In Development For The Acute Treatment Of Migraine
www.prnewswire.com - September 10 at 7:54 AM
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel